Use of apixaban after development of suspected rivaroxaban-induced hepatic steatosis; A case report

Blood Coagulation and Fibrinolysis

Volumn 26, Issue 6, 2015, Pages 699-702

  Anastasia, Emily J ^a   Rosenstein, Robert S ^a   Bergsman, Jeffrey A ^a   Parra, David ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Veterans Integrated Service Network 8   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Anticoagulants; Apixaban; Drug induced liver injury; Drug related sideeffects and adverse reactions; Factor Xa inhibitors; Fatty liver; Rivaroxaban

Indexed keywords

ALANINE AMINOTRANSFERASE; APIXABAN; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; RIVAROXABAN; WARFARIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ABDOMINAL RADIOGRAPHY; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CEREBROVASCULAR ACCIDENT; CREATININE CLEARANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBOLISM; FATTY LIVER; HUMAN; LIVER FUNCTION TEST; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; DRUG-INDUCED LIVER INJURY;

AGED; DRUG-INDUCED LIVER INJURY; HUMANS; MALE; PYRAZOLES; PYRIDONES; RIVAROXABAN;

EID: 84942615886     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000363     Document Type: Article

References (16)

1. Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2015.
2. Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, et al. Evaluations of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011; 34:243-252.
3. Caldeira D, Barra M, Santos AT, de Abreu D, Pinto FJ, Ferreira J, et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart 2014; 100:550-556.
4. Bjornsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther 2006; 79:521-528.
5. Cheetham TC, Lee J, Hunt CM, Niu F, Reisinger S, Murray R, et al. An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data. Pharmacoepidemiol Drug Saf 2014; 23:601-608.
6. Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hurlimann S, et al. Rivaroxaban postmarketing risk of liver injury. J Hepatol 2014; 61:293-300.
7. McGowan MP. There Is No Evidence for an Increase in Acute Coronary Syndromes After Short-Term Abrupt Discontinuation of Statins in Stable Cardiac Patients. Circulation 2004; 110:2333-2335.
8. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of International Consensus Meeting: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46:1323-1330.
9. Liakoni E, Ratz BravoAE, Terracciano L, HeimM, Krahenbuhl S.Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. JAMA Intern Med 2014; 174:1683-1686.
10. Barrett P, Vuppalanchi R, Masuoka H, Chalamsani N. Severe drug-induced skin and liver injury from rivaroxaban. Dig Dis Sci 2015; Epub ahead of print; doi: 10.1007/s10620-014-3504-9.
11. Arora N, Goldhaber SZ. Anticoagulants and transaminase elevations. Circulation 2006; 113:e698-e702.
12. Coumadin [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
13. Eliquis [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2014.
14. National Institute of Diabetes and Digestive and Kidney Diseases. 'Spironolactone' LiverTox. U.S. National Library of Medicine. Accessed Jan. 2015. http://livertox.nih.gov/Spironolactone.htm.
15. Moore TJ, Cohen MR, Furberg CD. Quarter Watch 2013 Quarter 1: Anticoagulation Update. Institute for Safe Medication Practices. URL: http://www.ismp.org/quarterwatch/pdfs/2013Q1.pdf
16. Heiduchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation. Europace 2013; 15:625-651.